{"id":"triamcinolone-nepafenac","safety":{"commonSideEffects":[{"rate":null,"effect":"Ocular irritation"},{"rate":null,"effect":"Corneal effects"},{"rate":null,"effect":"Increased intraocular pressure"},{"rate":null,"effect":"Conjunctival hyperemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Triamcinolone is a corticosteroid that suppresses inflammatory cytokines and immune cell activation by binding glucocorticoid receptors. Nepafenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase enzymes, reducing prostaglandin production. Together, they provide dual anti-inflammatory action for ocular conditions.","oneSentence":"Triamcinolone reduces inflammation via glucocorticoid receptor activation while nepafenac inhibits prostaglandin synthesis through COX inhibition, providing combined anti-inflammatory and analgesic effects.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:40:06.252Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Postoperative ocular inflammation and pain following cataract surgery"},{"name":"Ocular inflammation associated with ophthalmic procedures"}]},"trialDetails":[{"nctId":"NCT07276802","phase":"PHASE4","title":"The TRIBECA Study (TRIessence/Byqlovi for Easier CAtaract Surgery)","status":"NOT_YET_RECRUITING","sponsor":"Research Insight LLC","startDate":"2025-12-05","conditions":"Post Cataract Surgery","enrollment":40},{"nctId":"NCT00780780","phase":"PHASE3","title":"Efficacy Study of Triamcinolone Associated With Nepafenac for Treatment of Diabetic Macular Edema","status":"COMPLETED","sponsor":"Federal University of São Paulo","startDate":"2007-07","conditions":"Diabetic Macular Edema","enrollment":40},{"nctId":"NCT02515045","phase":"PHASE4","title":"Dropless vs. Standard Drops Contralateral Eye Study","status":"COMPLETED","sponsor":"Carolina Eyecare Physicians, LLC","startDate":"2015-01","conditions":"Cataract","enrollment":59}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":12,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Nepafenac (Nevanac)"],"phase":"phase_3","status":"active","brandName":"Triamcinolone + Nepafenac","genericName":"Triamcinolone + Nepafenac","companyName":"Federal University of São Paulo","companyId":"federal-university-of-s-o-paulo","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Triamcinolone and Nepafenac are used in eye care, with Nepafenac specifically inhibiting the enzyme Cyclooxygenase. They have been studied for conditions such as cataract, post-cataract surgery, and diabetic macular edema.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}